Orthocell Chairman John Van Der Wielen recently spoke with ausbiz about the Company’s strategic investment in Marine Biomedical and the rationale behind securing global distribution rights to PearlBone™.
John highlighted the strong clinical and commercial alignment between the two technologies in trauma settings, where surgeons often need to repair bone, nerve and tendon together, as well as the strategic timing of the investment as PearlBone prepares for FDA submission and leverages Orthocell’s established international distribution network.